Original new drugs generated by artificial intelligence systems entering phase II clinical trials | drugs | new drugs

Release time:Apr 13, 2024 23:46 PM

The reporter learned from Yingsi Intelligence yesterday that the candidate drug "INS018:055" developed by a foreign-funded enterprise in Shanghai for the treatment of idiopathic pulmonary fibrosis has completed the first patient administration in phase II clinical trials, marking the first candidate drug to be discovered and designed by generative artificial intelligence for new targets has advanced to the phase II clinical trials.

Professor Xu Zuojun, Chief Physician of Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, and Lead Researcher of INS018:055 Phase II Clinical Trials in China, introduced that idiopathic pulmonary fibrosis is a chronic scarring lung disease characterized by progressive and irreversible decline in lung function, affecting the lives and health of approximately 5 million people worldwide. Due to the hidden onset and progression of the disease, most patients are diagnosed with a condition that has progressed to the middle and late stages, with a median survival period of 3 years after diagnosis. Given the limited availability of existing therapies and overall poor prognosis, there are still significant unmet clinical needs in the field of IPF.

As an AI driven biopharmaceutical enterprise, Yingsi Intelligence has developed an end-to-end artificial intelligence pharmaceutical system, including target discovery platform PandaOmics, small molecule compound design and generation platform Chemistry42, and clinical trial result prediction platform InClinico.

Yingsi Intelligent "end-to-end" Drug Development Platform Pharma AI


Original new drugs generated by artificial intelligence systems entering phase II clinical trials | drugs | new drugs

The candidate new drug "INS018:055" for treating idiopathic pulmonary fibrosis was born from this system. Its target is novel and discovered by the PandaOmics platform. This platform analyzes omics data and text data pools to identify genetic differences between patients and healthy populations. Combined with comprehensive analysis of signal pathways, scientific literature, opinion leaders, and other information, it identifies the association between targets and diseases, and then discovers new targets for certain indications.

For the new target, the Chemistry42 platform designed and synthesized a batch of small molecule compounds using deep learning algorithms such as Generative Adversarial Networks. The R&D personnel conducted experimental tests on this batch of compounds and inputted the test data into Chemistry42. After deep learning the data, this platform synthesizes a batch of better compounds. In this way, after several rounds of "design synthesis testing optimization", Yingsi Intelligence identified preclinical candidate compounds.

"INS018:055 has the potential for anti fibrosis and anti-inflammatory effects, and is also the first AI designed drug to enter the clinical stage." Dr. Ren Feng, CEO and Chief Scientific Officer of Yingsi Intelligence, said, "The completion of the first phase II clinical trial for drug administration is an important progress in the AI pharmaceutical field. We look forward to it bringing new choices to patients worldwide."

Dr. Zavorokov collaborated with Dr. Ren Feng to develop a new drug.


Original new drugs generated by artificial intelligence systems entering phase II clinical trials | drugs | new drugs

It is understood that the Phase II clinical trial used a randomized, double-blind, placebo-controlled method to evaluate the safety, tolerability, pharmacokinetics, and efficacy of "INS018:055" oral administration for 12 weeks in the treatment of idiopathic pulmonary fibrosis in subjects, including four parallel cohorts. In order to test candidate drugs in a larger population, Yingsi Intelligent Plan recruited 60 patients with idiopathic pulmonary fibrosis from nearly 40 research centers in China and the United States, and conducted phase II clinical trials simultaneously.

Dr. Alex Zavorokov, founder and CEO of Yingsi Intelligence, said, "We will explore the effects of drugs discovered and designed by artificial intelligence on patients in clinical trials, which will be a true validation of generative artificial intelligence platforms."

Shanghai International Sister City Youth "Play" Summer Camp Experience Traditional Culture, Make Pankou, Learn Paper Cuttings, Make Dumplings International | Youth | Make Dumplings
Shanghai International Sister City Youth "Play" Summer Camp Experience Traditional Culture, Make Pankou, Learn Paper Cuttings, Make Dumplings International | Youth | Make Dumplings

Making coils, learning Paper Cuttings, making dumplings, walking into the home of summer camp volunteers and feeling the life of Shanghai people... On the 20th, the 2023 Shanghai International Sister City Youth Summer Camp officially opened in Shanghai Shidong Experimental School. 73 campers from 13 cities in 12 countries gathered in Shanghai to open the annual international sister city youth exchange event with their peers in Shanghai. The young partners together carried out activities such as learning excellent traditional Chinese culture courses such as Chinese and traditional Chinese painting, intangible cultural heritage, Chinese clothing, disco, Paper Cuttings, seal cutting, calligraphy, pottery, tea art, Yanzhi, dragon dance, youth forum exchanges in sister cities, investigation of urban cultural landscape, visits to universities and venues, city orientation challenges, and local family life experiences, etc., to bloom their youth. In addition to a rich and colorful summer camp physical activity experience, campers and volunteers

Undergraduate voluntary application starts today! These important reminders and suggestions must be read, @ College Entrance Examination Stage | Undergraduate | Volunteer
Undergraduate voluntary application starts today! These important reminders and suggestions must be read, @ College Entrance Examination Stage | Undergraduate | Volunteer

@All college entrance examination candidates, according to the schedule of the college entrance examination, will fill in their undergraduate preferences for all batches except for the comprehensive evaluation batch from 8:00 a.m. to 8:00 p.m. daily from July 1st to 2nd, and from 8:00 a.m. to 12:00 a.m. on July 3rd. The specific contents of this voluntary application include zero voluntary batch, advance batch, art and sports class A batch, local rural special plan batch, special type enrollment, and ordinary batch. The filling method is as follows: Fresh high school graduates in this city will be arranged uniformly by the high school where they are enrolled; Non local fresh high school graduates will be arranged uniformly by the district recruitment office where they apply. It is important to remind candidates that during the voluntary application period from July 1st to 3rd, as the admission of the comprehensive evaluation batch has not yet been completed, candidates who have filled out the comprehensive evaluation batch of voluntary applications still need to carefully fill out other batches of undergraduate voluntary applications

Investment+Services Drive Anti Cancer Drugs into Clinical Practice | Entrepreneurial Stories in Incubators, Second Entrepreneurial Biology for CEOs of Listed Companies | Incubators | Clinical | Incubators
Investment+Services Drive Anti Cancer Drugs into Clinical Practice | Entrepreneurial Stories in Incubators, Second Entrepreneurial Biology for CEOs of Listed Companies | Incubators | Clinical | Incubators

Recently, with the approval of the National Medical Products Administration, the Class 1 innovative drug CC312 developed by Huihe Biotechnology has initiated phase I clinical trials for the treatment of recurrent/refractory CD19 positive B-cell malignant hematological tumors. This is the first domestically and the third globally approved triple specific antibody drug based on CD28 co stimulatory signals to enter clinical practice. When it comes to the development history of this new triple antibody drug, Dr. Zhu Huaxing, the founder of Huihe Biotechnology, still remembers vividly: "Before 2019, there was no triple antibody drug approved for clinical use globally, and some investors couldn't understand CC312. During a critical period of company development, Nokai Xinkang Fund invested 30 million yuan to help us complete Series A financing." Nokai Xinkang is a venture capital fund initiated by Xinze Entrepreneurship Incubator. This incubation company, which has been deeply cultivated in Zhangjiang Science City for many years

"Zidong Taichu" Full Modal Large Model Released, Precisely Positioned 3D Scene, Listening to "Moonlight Song" and Talking about Beethoven Images | Applications | Beethoven
"Zidong Taichu" Full Modal Large Model Released, Precisely Positioned 3D Scene, Listening to "Moonlight Song" and Talking about Beethoven Images | Applications | Beethoven

Not only can you hear Beethoven talk freely in "Moonlight", but you can also achieve precise positioning in three-dimensional scenes, and complete scene analysis through the combination of images and sound. On June 16, at the AI Framework Ecological Summit, the Institute of Automation of the Chinese Academy of Sciences officially released the full mode large model of "Zidong Taichu". This model is the 2.0 version upgraded from the 1.0 version of the 100 billion parameter multimodal model "Zidong Taichu". On the basis of voice, image and text three modes, it adds video, sensor signal, 3D point cloud and other modal data, breaks through the key technologies such as multimodal correlation for cognitive enhancement, and has full modal understanding, generation and correlation capabilities. At the meeting, Xu Bo, the director of the Institute of Automation, presented for the first time in real time the "Zidong Taichu" full modal cognitive model in music understanding

Perseverance is a life experience. Lingling Middle School has weak muscles. Candidates complete the college entrance examination: no matter what difficulties they experience. High school | school | college entrance examination
Perseverance is a life experience. Lingling Middle School has weak muscles. Candidates complete the college entrance examination: no matter what difficulties they experience. High school | school | college entrance examination

"The college entrance examination is an experience in our lives. Looking back on the preparation for the entire senior year of high school, we cannot help but marvel at the preciousness of time. No matter what difficulties we have gone through, I believe that as long as we persist, it will become my lifelong wealth. Today, after completing the morning foreign language listening and speaking test of the college entrance examination, Xiao Song, a senior student of Lingling High School, came out of the examination center of East China University of Science and Technology Affiliated Middle School. The senior year graduate sitting in a wheelchair said," Although academic and life are not small tests for me, I have faced many difficulties in adversity and have never given up on my dream of taking the college entrance examination. "Xiao Song suffered from congenital muscular dystrophy since childhood and entered Lingling High School in high school." Later, the school provided him with classrooms on low floors and close to the toilet, making it easier for him to enter and exit, allowing him to face his academic life with more confidence. At school, I met many kind and enthusiastic people